Carrier Screening Market | Growth, Trends, and Forecast (2019-2024)

Carrier Screening Market - Growth, Trends, and Forecast (2019 - 2024)

The market is segmented by Test Type (Molecular Screening Test, and Biochemical Screening Test), Disease Type, and Geography

PURCHASE REPORT

Carrier Screening Market 1

Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Key Players:

PURCHASE REPORT

Market Overview

The major factors for the growth of the carrier screening market include the increasing emphasis on early disease detection and prevention, growing demand for personalized medicine, and increasing application of screening tests in genetic disorders is expected to experience a boost in the forecast period.

The earlier a disease is diagnosed, the more likely it can be cured or successfully managed. Treating the disease early could also make the disease easier to live with. Early disease detection helps people plan ahead, while they are still able to make important decisions on their health & support needs and on financial & legal matters. Genetic diseases, such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease, are inherited disorders. Carrier testing for such diseases can provide information about a couple’s risk of having a child with a genetic condition. Identification of the risk, prior to the onset of symptoms is called predictive/presymptomatic testing. Many genetic disorders can be detected early in pregnancy. So, the consumer demand for safe and effective carrier tests is fueling the growth of this market. In addition, the adoption of carrier tests into regular clinical care offers a commercial advantage to the market. According to many studies, early detection of disease can prevent the disease completely or at least decrease the complications of the disease. Healthcare organizations in several countries are funding newborn screening to predict diseases like cancers, which may occur later in adulthood.

Scope of the Report

As per the scope of the report, carrier screening is a type of genetic test to identify the autosomal recessive genetic disorders before or during a pregnancy stage. Further, it helps in identifying a child with a genetic disorder. The market is segmented on the basis of screening test type (molecular screening test/biochemical screening test), disease type (cystic fibrosis, Tay-Sachs disease, sickle cell disease, gaucher disease, spinal muscular atrophy, and other autosomal recessive genetic disorders). In developed countries, such as the United States, Germany, and France, among others, the demand for screening tests for the risk of genetic diseases is driving the market’s growth.

Test Type
Molecular Screening Test
Biochemical Screening Test
Disease Type
Cystic Fibrosis
Tay-Sachs
Gaucher Disease
Sickle Cell Disease
Spinal Muscular Atrophy
Other Autosomal Recessive Genetic Disorders
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
  • MARKET SEGMENTATION
    • Test Type
      • Molecular Screening Test
      • Biochemical Screening Test
    • Disease Type
      • Cystic Fibrosis
      • Tay-Sachs
      • Gaucher Disease
      • Sickle Cell Disease
      • Spinal Muscular Atrophy
      • Other Autosomal Recessive Genetic Disorders
    • Geography
      • North America
        • US
        • Canada
        • Mexico
      • Europe
        • Germany
        • UK
        • France
        • Italy
        • Spain
        • Rest of Europe
      • Asia Pacific
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • Rest of Asia-Pacific
      • Middle East and Africa
        • GCC
        • South Africa
        • Rest of Middle East and Africa
      • South America
        • Brazil
        • Argentina
        • Rest of South America

Key Market Trends

Molecular Screening Test Segment by Test Type is Expected to Register Fastest Growth Rate during the Forecast Period

A molecular screening test identifies DNA mutations, which are variations in the genetic code that lead to decreased production of enzymes. It focusses on the mutations seen in one ethnic group. It involves a stepwise process of testing for common alleles and if required extensive gene analysis. A method of molecular screening is sequencing, which is accomplished by reading across the DNA code of a specific gene to know if there are any known mutations. If the test results are negative, it reduces the chances that the individual is a carrier, however, it does not eliminate the chance of having a carrier gene since it is possible that the mutation might not have been discovered yet through the current technology.

Some of the prominent recessive disorders for which molecular testing is beneficial are Canavan disease, Cystic fibrosis, GM1 gangliosidosis, spinal muscular atrophy, etc. With the advancement in the genetic analysis tools like assays based on next-generation sequencing and microarray technologies, molecular diagnostics are revolutionizing the practice of medicine by improving the prenatal and reproductive care, enabling earlier disease detection and advancing the treatment for heritable diseases. There is an expansion of molecular testing as it has the potential to raise the testing accuracies through technical benefits for many targeted disorders that may not be suggested to biochemical testing.

Carrier Screening Market 2

North America accounted for the Largest Share in the Global Market

North America is found to hold a major share for the carrier screening market and is expected to show a similar trend over the forecast period, without significant fluctuations. Genetic disease is the leading cause of infant death in the United States, accounting for approximately 20% of the total annual infant mortality. Many advances in genomic medicine and technological platforms have made possible for low cost, pan‐ethnic expanded carrier screening that enables obstetric care providers to offer screening for over the 100 recessive genetic diseases. However, the rapid integration of this genomic medicine into the routine obstetric practice has raised some concerns about the practical implementation of carrier testing. According to the Cystic Fibrosis Foundation, more than 30,000 people are living with cystic fibrosis in the United States, and approximately 1,000 new cases of cystic fibrosis are diagnosed each year in the country. Thus, as the prevalence of genetic diseases is increasing every year, the usage of carrier screening is also expected to increase during the forecast period.

Carrier Screening Market 3

Competitive Landscape

The presence of major market players, such as Abbott, F. Hoffmann-La Roche AG, Cepheid (Danaher Corporation), Illumina Inc., and Thermo Fisher Scientific Inc, in turn are increasing the overall competitive rivalry of the market. Most of the market players are expanding their technologies through acquisitions and partnerships. For instance, in January 2017 Philips and Illumina collaborated to offer the integrated genomics solutions for oncology.

Major Players

  1. Abbott Laboratories
  2. F. Hoffmann-La Roche AG
  3. Cepheid (Danaher Corporation)
  4. Illumina Inc.
  5. Thermo Fisher Scientific Inc.

* Complete list of players covered available in the table of contents below

Carrier Screening Market 4

Customize the Report

80% of our clients ask for some sort of customisation, be it specific countries / companies / segments.

What are you looking for?

Please Enter a Valid Email ID!

Please Enter a Valid Message!

Table of Contents

  1. INTRODUCTION
    1. Study Deliverables
    2. Study Assumptions
    3. Scope of the Study
  2. RESEARCH METHODOLOGY
  3. EXECUTIVE SUMMARY
  4. MARKET DYNAMICS
    1. Market Overview
    2. Market Drivers
      1. Increasing Emphasis on Early-disease Detection and Prevention
      2. Growing Demand for Personalized Medicine
      3. Increasing Application of Screening Tests in Genetic Disorders
    3. Market Restraints
      1. Social and Ethical Implications of Carrier Screening
      2. High Costs of Carrier Testing
      3. Reimbursement Issues
    4. Porter's Five Force Analysis
      1. Threat of New Entrants
      2. Bargaining Power of Buyers/Consumers
      3. Bargaining Power of Suppliers
      4. Threat of Substitute Products
      5. Intensity of Competitive Rivalry
  5. MARKET SEGMENTATION
    1. Test Type
      1. Molecular Screening Test
      2. Biochemical Screening Test
    2. Disease Type
      1. Cystic Fibrosis
      2. Tay-Sachs
      3. Gaucher Disease
      4. Sickle Cell Disease
      5. Spinal Muscular Atrophy
      6. Other Autosomal Recessive Genetic Disorders
    3. Geography
      1. North America
        1. US
        2. Canada
        3. Mexico
      2. Europe
        1. Germany
        2. UK
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
      3. Asia Pacific
        1. China
        2. Japan
        3. India
        4. Australia
        5. South Korea
        6. Rest of Asia-Pacific
      4. Middle East and Africa
        1. GCC
        2. South Africa
        3. Rest of Middle East and Africa
      5. South America
        1. Brazil
        2. Argentina
        3. Rest of South America
  6. COMPETITIVE LANDSCAPE
    1. Company Profiles
      1. 23Andme Inc.
      2. Abbott Laboratories
      3. F. Hoffmann-La Roche AG
      4. Cepheid (Danaher Corporation)
      5. Illumina Inc.
      6. Luminex Corporation
      7. Sequenom Inc. (Laboratory Corporation of America�Holdings)
      8. Myriad Genetics
      9. Autogenomics Inc.
      10. Thermo Fisher Scientific Inc.
    2. *List Not Exhaustive
  7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments